Graves眼病致病基因研究现状
Current Research on the Pathogenic Genes of Graves Disease
DOI: 10.12677/acm.2024.14102793, PDF,   
作者: 林经树:右江民族医学院研究生学院,广西 百色;韦 华:右江民族医学院全科医学院,广西 百色
关键词: 致病基因Graves眼病Pathogenic Genes Graves Disease
摘要: Graves眼病是Graves病中最常见的甲状腺腺外表现之一,主要表现为眼球突出、眼睑水肿退缩和眼眶周围组织红斑等症状。如果不及时治疗,病情会进一步恶化,可能会影响患者的视力,甚至导致失明。Graves眼病的发病机制尚未完全明确,受众多因素共同作用,但基因是其中主要的影响因素之一。目前认为,Graves眼病是由多个基因共同调控的,不同的基因可能引起相同的病症表现(基因多态性),而同一个基因也可能引起不同的病症表现(基因多效性)。有些人携带突变基因却没有出现相应的病症(不完全表型),而另一些人没有Graves眼病,但却有不同的基因突变(多基因遗传)。Graves眼病的发生是由不同的基因与基因、基因与环境相互作用引起的。Graves眼病相关的基因的研究方法有基因谱扫描、候选基因技术和连锁分析等。Graves眼病相关的基因已经发现了多个。下面是关于Graves眼病相关基因的概述。
Abstract: Graves ophthalmopathy is one of the most common extra thyroid manifestations in Graves’ disease. Symptoms include eyeball protrusion, eyelid edema, eyelid retreat and erythema of periorbital tissue. If left untreated, the disease can progress which may affect the patient’s vision and even lead to blindness. The pathogenesis of Graves ophthalmopathy is still unknown. For Graves ophthalmopathy, many factors work together, but genes are one of the main influencing factors. At present, it is believed that Graves eye disease is regulated by multiple genes. Different genes may cause the same disease (gene polymorphism), while the same gene may also cause different manifestations of the disease (gene pleiotropy). Some people carry the mutated gene without developing the corresponding disorder (incomplete phenotype), while others do not have Graves eye disease, but with a different genetic mutation (polygenic inheritance). Graves eye disease is caused by the interaction of different genes with genes and genes with the environment. The research methods on genes related to Graves eye disease include gene profile scanning, candidate gene technique and linkage analysis. Graves eye disease associated genes have been found several. The following is an overview of the genes associated with Graves eye disease.
文章引用:林经树, 韦华. Graves眼病致病基因研究现状[J]. 临床医学进展, 2024, 14(10): 1247-1251. https://doi.org/10.12677/acm.2024.14102793

参考文献

[1] 张美琴. TNFSF15基因多态性与Graves眼病遗传易感性研究[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2020.
[2] Zhou, F., Liang, Z., Wang, X., Tan, G., Wei, W., Zheng, G., et al. (2021) The VDR Gene Confers a Genetic Predisposition to Graves’ Disease and Graves’ Ophthalmopathy in the Southwest Chinese Han Population. Gene, 793, Article ID: 145750. [Google Scholar] [CrossRef] [PubMed]
[3] Maciejewski, A., Kowalczyk, M.J., Gasińska, T., Szeliga, A., Prendecki, M., Dorszewska, J., et al. (2019) The Role of Vitamin D Receptor Gene Polymorphisms in Thyroid-Associated Orbitopathy. Ocular Immunology and Inflammation, 28, 354-361. [Google Scholar] [CrossRef] [PubMed]
[4] Paik, J.S., Kim, S., Kim, J.H., Lee, J., Yang, S. and Lee, S. (2020) Insulin-like Growth Factor-1 Enhances the Expression of Functional TSH Receptor in Orbital Fibroblasts from Thyroid-Associated Ophthalmopathy. Immunobiology, 225, Article ID: 151902. [Google Scholar] [CrossRef] [PubMed]
[5] Smith, T.J. (2021) Insulin-like Growth Factor Pathway and the Thyroid. Frontiers in Endocrinology, 12, Article 653627. [Google Scholar] [CrossRef] [PubMed]
[6] 刘雪. IGF-IR在甲状腺相关眼病中的作用机制及相关治疗进展[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2019.
[7] Krieger, C.C., Sui, X., Kahaly, G.J., Neumann, S. and Gershengorn, M.C. (2021) Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease. The Journal of Clinical Endocrinology & Metabolism, 107, e1653-e1660. [Google Scholar] [CrossRef] [PubMed]
[8] Fernando, R., Caldera, O. and Smith, T.J. (2021) Therapeutic IGF-I Receptor Inhibition Alters Fibrocyte Immune Phenotype in Thyroid-Associated Ophthalmopathy. Proceedings of the National Academy of Sciences of the United States of America, 118, e2114244118. [Google Scholar] [CrossRef] [PubMed]
[9] Li, Q., Yang, C., Liu, C., Zhang, Y., An, N., Ma, X., et al. (2024) The Circulating Il-35+ Regulatory B Cells Are Associated with Thyroid Associated Opthalmopathy. Immunity, Inflammation and Disease, 12, e1304. [Google Scholar] [CrossRef] [PubMed]
[10] Pan, Y., Wang, M., Chen, X., Chen, Y., Ai, S., Wang, M., et al. (2021) Elevated IL-38 Inhibits IL-23R Expression and IL-17A Production in Thyroid-Associated Ophthalmopathy. International Immunopharmacology, 91, Article ID: 107300. [Google Scholar] [CrossRef] [PubMed]
[11] Shi, L., Ye, H., Huang, J., Li, Y., Wang, X., Xu, Z., et al. (2021) IL-38 Exerts Anti-Inflammatory and Antifibrotic Effects in Thyroid-Associated Ophthalmopathy. The Journal of Clinical Endocrinology & Metabolism, 106, e3125-e3142. [Google Scholar] [CrossRef] [PubMed]
[12] Du, J., Wang, X., Tan, G., Wei, W., Zhou, F., Liang, Z., et al. (2021) Predisposition to Graves’ Disease and Graves’ Ophthalmopathy by Genetic Variants of IL2RA. Journal of Molecular Medicine, 99, 1487-1495. [Google Scholar] [CrossRef] [PubMed]
[13] Stöhr, M., Oeverhaus, M., Lytton, S.D., Horstmann, M., Zwanziger, D., Möller, L., et al. (2021) Predicting the Relapse of Hyperthyroidism in Treated Graves’ Disease with Orbitopathy by Serial Measurements of TSH-Receptor Autoantibodies. Hormone and Metabolic Research, 53, 235-244. [Google Scholar] [CrossRef] [PubMed]
[14] Nicolì, F., Lanzolla, G., Mantuano, M., Ionni, I., Mazzi, B., Leo, M., et al. (2020) Correlation between Serum Anti-TSH Receptor Autoantibodies (TRABs) and the Clinical Feature of Graves’ Orbitopathy. Journal of Endocrinological Investigation, 44, 581-585. [Google Scholar] [CrossRef] [PubMed]
[15] 王靖文, 柳林, 马晓婧, 刘梦妍, 高素敏. TSHR基因内含子1多态性与山东潍坊地区汉族人群Graves’眼病关系分析[J]. 潍坊医学院学报, 2021, 43(3): 192-195, 199.
[16] 马超, 刘薇, 李凯军, 何剑峰. 甲状腺相关眼病免疫相关发病机制的研究现状与进展[J]. 眼科新进展, 2019, 39(8): 790-794.
[17] 冯晓婷. 225例甲状腺相关眼病患者的临床资料分析和核磁共振脂肪定量对评估病情的临床应用初探[D]: [硕士学位论文]. 广州: 南方医科大学, 2019.
[18] 刘莹, 朱武飞, 赵雅. 甲状腺相关眼病的临床防治进展[J]. 中国医药科学, 2023, 13(21): 53-56.
[19] Janssen, J.A.M.J.L. and Smith, T.J. (2021) Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy. Cells, 10, Article 383. [Google Scholar] [CrossRef] [PubMed]
[20] 王璇璐, 彭年春, 胡颖. 中重度活动性Graves眼病药物治疗新进展[J]. 疑难病杂志, 2024, 23(5): 635-640.